Table 2.
Baseline renal measures of the patient groups
| Measures | Regular-Dose (n=24) | Dose-Reduction-Switch (n=28) | Switch (n=37) | Total (N=89) |
|---|---|---|---|---|
| Creatinine, mg/dl | 2.05±2.49 | 1.49±1.58 | 1.89±2.63 | 1.82±2.31 |
| Creatinine, mg/dla | 1.19±0.48b | 0.82±0.18 | 1.01±0.33 | 0.99±0.35 |
| Cystatin C, mg/l | 1.53±1.43 | 1.39±1.29 | 1.07±0.54 | 1.32±1.10 |
| Cystatin C, mg/la | 1.02±0.51 | 0.76±0.14 | 0.98±0.39 | 0.93±0.39 |
| eGFR, ml/min per 1.73 m2 | ||||
| eGFRcreat | 69.9±36.6 | 74.2±34.5 | 72.8±35.9 | 72.5±35.2 |
| eGFRcreata | 81.9±28.0 | 86.5±24.4 | 81.9±21.0 | 83.3±23.1 |
| eGFRcys | 79.9±42.4 | 91.1±46.7 | 89.4±37.9 | 87.4±41.4 |
| eGFRcysa | 89.7±29.3 | 114.2±25.0 | 92.1±31.6 | 97.4±30.5 |
| eGFRcreat-cys | 73.7±39.9 | 83.3±41.2 | 83.7±34.1 | 80.2±38.9 |
| eGFRcreat-cysa | 87.1±31.5 | 95.3±28.6 | 86.7±25.8 | 89.2±27.4 |
| ACR, mg/g creatinine | 185±264 | 324±373 | 189±300 | 226.3±301 |
| Albuminuria | 9 (69.2) | 9 (75.0) | 12 (70.6) | 30 (71.4) |
| Hemoglobin, mg/dl | 13.7±1.1 | 13.8±1.2 | 13.5±1.6 | 13.6±1.4 |
| Kidney transplantation | 3 (13.0) | 4 (14.8) | 2 (5.9) | 9 (10.7) |
| Dialysis | 8 (34.8) | 4 (14.8) | 5 (14.7) | 17 (20.2) |
| Hyperfiltration | 0 (0.0) | 1 (3.6) | 1 (2.7) | 2 (2.2) |
Values are given as mean±SD or n (%). Differences between groups have been tested via one-way ANOVA for continuous variables or Fisher’s exact test for categorical variables. Because of the multicenter approach, some parameters were not available for the entire study cohort. eGFRcreat is calculated via the CKD-EPI formula according to Levey et al.14 eGFRcys and eGFRcreat-cys are calculated via the CKD-EPI formula according to Inker et al.15 Albuminuria, ACR>30 mg/g protein; hyperfiltration, eGFRcreat>120 ml/min per 1.73 m2.
a
Values without patients with kidney transplantation, dialysis, or hyperfiltration.
b
P<0.05 for regular-dose versus dose-reduction-switch group.